Case-Based Peer Perspectives: A 65-Year-Old Man Diagnosed with PSMA-positive mCRPC

home / case-based-peer-perspectives / case-based-peer-perspectives-a-65-year-old-man-diagnosed-with-psma-positive-mcrpc

Neal Shore, MD, FACS discusses how a 65-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) underwent a treatment journey that included androgen deprivation therapy, docetaxel, cabazitaxel, and enzalutamide before ultimately being evaluated for Lutetium-177 therapy based on PSMA PET imaging and trial data.

Patient Case 1: A Sixty-Five-Year-Old Man With Prostate Cancer

EP. 1: Patient Case 1: A Sixty-Five-Year-Old Man With Prostate Cancer

Neal Shore, MD, FACS
September 30th 2024

Neal Shore, MD, FACS, discusses the progress of a 65-year-old patient with mCRPC through various treatments and evaluation for Lutetium-177 therapy based on his PSMA PET scan and MRI.

PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

EP. 2: PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

Neal Shore, MD, FACS
October 7th 2024

Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the crucial role of PSMA PET imaging in determining treatment suitability.

© 2024 MJH Life Sciences

All rights reserved.